Progress in Cardiovascular Diseases
Volume 53, Issue 1 , Pages 45-51 , July 2010

The Framingham Study, Diabetes Mellitus and Cardiovascular Disease: Turning Back the Clock

  • Andre Pascal Kengne

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Andre Pascal Kengne, MD, PhD, The George Institute for International Health, University of Sydney, PO Box M201, Level 10 KGV Bldg, RPAH, Missenden Rd, Camperdown, Sydney NSW 2050, Australia.
    • ,
  • Fiona Turnbull
    • ,
  • Stephen MacMahon

References 

  1. International Diabetes Federation . Diabetes atlas. 4th ed. Brussels: IDF; 2009;
  2. International Diabetes Federation . Diabetes atlas. 2nd ed. Brussels: IDF; 2003;
  3. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation. 1999;100:1132–1133
  4. Danaei G, Lawes CM, Vander Hoorn S, et al. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet. 2006;368:1651–1659
  5. International Task Force for Prevention of Coronary Heart Disease  International Atherosclerosis Society. Pocket guide to prevention of coronary heart disease. Munster: Born Bruckmeier Verlag GmbH; 2003;
  6. Hegglin P. Über Kreislaufprobleme bei gestörtem Zuckerstoffwechsel, insbesondere im Coma diabeticum. Basic Res Cardiol. 1940;3:1–53
  7. Mayer J. On diabetes and its connection with heart disease. BMJ. 1888;1:949–951
  8. Millard EB, Root HF. Degenerative vascular lesions and diabetes mellitus. Am J Dig Dis. 1948;15:41–51
  9. Smith KS. Cardiac syndromes complicating diabetes and their treatment. Heart. 1943;5:1–7
  10. Marks H, Krall L. Onset, course, prognosis and mortality in diabetes mellitus. In:  Marble A,  White P,  Bradley R,  Krall L editor. Joslin's diabetes mellitus. 11th ed. Philadelphia: Lea & Febiger; 1971;p. 209–254
  11. Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987;3:463–524
  12. Entmacher PS, Root HF, Marks HH. Longevity of diabetic patients in recent years. Diabetes. 1964;13:373–377
  13. Krolewski AS, Czyzyk A, Janeczko D, et al. Mortality from cardiovascular diseases among diabetics. Diabetologia. 1977;13:345–350
  14. Pell S, D'Alonzo CA. Factors associated with long-term survival of diabetics. JAMA. 1970;214:1833–1840
  15. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035–2038
  16. Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes. 1974;23:105–111
  17. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34
  18. Kannel WB, McNamara PM, Feinleib M, et al. The unrecognized myocardial infarction. Fourteen-year follow-up experience in the Framingham study. Geriatrics. 1970;25:75–87
  19. Kannel WB, Wilson PW, D'Agostino RB, et al. Sudden coronary death in women. Am Heart J. 1998;136:205–212
  20. Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. Diabetes. 1989;38:504–509
  21. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840–844
  22. Wong ND, Cupples LA, Ostfeld AM, et al. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Am J Epidemiol. 1989;130:469–480
  23. Abbott RD, Donahue RP, Kannel WB, et al. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA. 1988;260:3456–3460
  24. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):789–830
  25. Robertson WB, Strong JP. Atherosclerosis in persons with hypertension and diabetes mellitus. Lab Invest. 1968;18:538–551
  26. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetes Drafting Group. Diabetologia. 1985;28(Suppl):615–640
  27. The International Collaborative Group. Asymptomatic hyperglycemia and coronary heart disease. A series of papers by the International Collaborative Group, based on studies in fifteen populations. J Chronic Dis. 1979;32:681–837
  28. Wilson PW, Cupples LA, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J. 1991;121:586–590
  29. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979;2:120–126
  30. Levitzky YS, Pencina MJ, D'Agostino RB, et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol. 2008;51:264–270
  31. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007;115:1544–1550
  32. Kannel WB, Wolf PA, Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA. 1983;250:2942–2946
  33. Asia Pacific Cohort Studies Collaboration. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care. 2004;27:2836–2842
  34. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233–240
  35. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–431
  36. Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham study. Circulation. 1979;59:8–13
  37. Asia Pacific Cohort Studies Collaboration. Smoking, diabetes and cardiovascular diseases in men in the Asia-Pacific region. J Diabetes. 2009;1:173–181
  38. Asia Pacific Cohort Studies Collaboration. Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region. Diabetologia. 2007;50:2289–2297
  39. Asia Pacific Cohort Studies Collaboration. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens. 2007;25:1205–1213
  40. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure–lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165:1410–1419
  41. Costa J, Borges M, David C, et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006;332:1115–1124
  42. Preis SR, Pencina MJ, Hwang SJ, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009;120:212–220
  43. Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA. 2004;292:2495–2499
  44. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009;119:1728–1735
  45. Fox CS, Pencina MJ, Wilson PW, et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care. 2008;31:1582–1584
  46. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113:791–798
  47. Truett J, Cornfield J, Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis. 1967;20:511–524
  48. Walker SH, Duncan DB. Estimation of the probability of an event as a function of several independent variables. Biometrika. 1967;54:167–179
  49. Murabito JM, D'Agostino RB, Silbershatz H, et al. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997;96:44–49
  50. Anderson KM, Odell PM, Wilson PW, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–298
  51. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol. 1976;38:46–51
  52. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847
  53. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753
  54. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671–679
  55. Chamnan P, Simmons RK, Sharp SJ, et al. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia. 2009;52:2001–2014
  56. Kengne AP, Patel A, Colagiuri S, et al. The Framingham and UKPDS risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia. 2010;
  57. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589
  58. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  59. Kelly TN, Bazzano LA, Fonseca VA, et al. Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med. 2009;151:1–10
  60. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772
  61. Stettler C, Allemann S, Juni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152:27–38
  62. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288–2298

 Statement on Conflict of Interest: see page 49.

PII: S0033-0620(10)00039-3

doi: 10.1016/j.pcad.2010.02.010

Progress in Cardiovascular Diseases
Volume 53, Issue 1 , Pages 45-51 , July 2010

Article Tools

* Image Usage & Resolution